Acuity reported second-quarter earnings today and met analysts' expectations. Its sales grew by 20% and its adjusted earnings ...

Children with amblyopia who used the AmblyoPlay app 5 days a week for 6 months had significant improvements in visual acuity, ...

Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...

Turkey: A pilot study published in BMC Ophthalmology suggests that a gamified, app-based multimodal visual therapy may offer ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

The Light Adjustable Lens (LAL) enables rapid achievement of excellent visual acuity, often reaching 20/25 or 20/20 on the first postoperative day. Patient selection is crucial; detail-oriented ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...

Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028DURHAM, N.C., Jan. 08, 2026 (GLOBE ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – ...

Ocugen (OCGN) rated Buy as OCU410ST Stargardt trial advances; FDA/EMA alignment speeds path to approval. Read here for more ...

Seasoned biopharma industry leader brings more than 30 years of experience to support company’s growth trajectory —BERKELEY, Calif.--(BUSINESS WIRE)--Ray Therapeutics, a clinical-stage biotechnology ...

OSN Cornea/External Disease Board Member Eric D. Donnenfeld, MD, and a panel of experts examined a series of unusual ...